Originally published July 29.

NEW YORK (GenomeWeb) – AstraZeneca is exploring the use of liquid biopsy-based companion tests to pick out best responders for its drugs for lung cancer, where acquiring biopsy tissue is particularly challenging for advanced patients.

The drugmaker this week announced two deals, one with Qiagen and another with Roche, to advance liquid biopsy-based companion diagnostics for its marketed non-small cell lung cancer drug Iressa (gefitinib) and the investigational NSCLC agent AZD9291, respectively.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.